Impact of Reality Extra Analgesic on Liver and Kidney Function in Male Rats
DOI:
https://doi.org/10.58987/1t513q66Keywords:
Paracetamol, Caffein, Diclofenac, Aspartate aminotransferaseAbstract
In this study, we assessed how Reality Extra (RE), a popular analgesic composed of caffeine, diclofenac sodium, and paracetamol, affected in albino rats. Two groups of rats were formed; one group received Reality Extra for 12 days, while the other group was given saline as a control group. To evaluate the effects of the medication, a number of biological and enzymatic indicators were examined, such as blood urea levels, plasma bilirubin and creatinine levels, body weight gain, liver weight, and plasma aspartate aminotransferase (AST) and alanine transaminase (ALT) enzyme activities. Rats treated with Reality Extra had significantly higher levels of AST, ALT, and creatinine as well as significantly lower urea levels as compared to the control group. Furthermore, the rats given Reality Extra showed a non-significant drop in bilirubin levels. These results suggest that RE may negatively impact kidney and liver function, highlighting the need for more comprehensive research in diverse clinical contexts.
References
[1] K. Brune, B. Renner, G. Tiegs, “Acetaminophen/paracetamol: a history of errors, failures and false decisions,” Eur. J. Pain, Vol. 19(7), 953–965, 2015. DOI: https://doi.org/10.1002/ejp.621
[2] K. Anneken, S. Evers, I. W. Husstedt, “Efficacy of fixed combinations of acetylsalicylic acid, acetaminophen and caffeine in the treatment of idiopathic headache: a review,” Eur. J. Neurol., Vol. 17(4), 534–e25, 2010. DOI: https://doi.org/10.1111/j.1468-1331.2009.02922.x
[3] V. Pfaffenrath, H. C. Diener, L. Pageler, H. Peil, B. Aicher, “OTC analgesics in headache treatment: open-label phase vs randomized double-blind phase of a large clinical trial,” Headache, Vol. 49(5), 638–645, 2009. DOI: https://doi.org/10.1111/j.1526-4610.2009.01402.x
[4] J. Goldstein, S. D. Silberstein, J. R. Saper, R. E. Ryan Jr., R. B. Lipton, “Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study,” Headache, Vol. 46(3), 444–453, 2006. DOI: https://doi.org/10.1111/j.1526-4610.2006.00376.x
[5] J. M. Dooley, K. E. Gordon, E. P. Wood, P. M. Brna, J. MacSween, A. Fraser, “Caffeine as an adjuvant to ibuprofen in treating childhood headaches,” Pediatr. Neurol., Vol. 37(1), 42–46, 2007. DOI: https://doi.org/10.1016/j.pediatrneurol.2007.02.016
[6] B. Renner, G. Clarke, T. Grattan, A. Beisel, C. Mueller, U. Werner, G. Kobal, K. Brune, “Caffeine accelerates absorption and enhances the analgesic effect of acetaminophen,” J. Clin. Pharmacol., Vol. 47(6), 715–726, 2007. DOI: https://doi.org/10.1177/0091270007299762
[7] C. Sato, N. Izumi, T. Nouchi, Y. Hasumura, J. Takeuchi, “Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat,” Toxicology, Vol. 34(2), 95–101, 1985. DOI: https://doi.org/10.1016/0300-483X(85)90159-3
[8] M. D. Cameron, B. Wen, A. G. Roberts, W. M. Atkins, P. A. Campbell, S. D. Nelson, “Cooperative binding of acetaminophen and caffeine within the P450 3A4 active site,” Chem. Res. Toxicol., Vol. 20(10), 1434–1441, 2007. DOI: https://doi.org/10.1021/tx7000702
[9] E. Oksuz, S. Yasar, R. Erten, O. Arihan, G. Oto, “Comparison of effects of high and low dose paracetamol treatment and toxicity on brain and liver in rats,” North. Clin. Istanbul, Vol. 7(6), 2020. DOI: https://doi.org/10.14744/nci.2020.54926
[10] T. S. Abiola, O. C. Adebayo, O. O. Babalola, “Diclofenac-induced kidney damage in wistar rats: involvement of antioxidant mechanism,” J. Biosci. Med., Vol. 7(12), 44–52, 2019. DOI: https://doi.org/10.4236/jbm.2019.712005
[11] B. Bannwarth, F. Pehourcq, “Pharmacological rationale for the clinical use of paracetamol: pharmacokinetic and pharmacodynamic issues,” Drugs, Vol. 63, 5–13, 2003. DOI: https://doi.org/10.2165/00003495-200363992-00003
[12] H. C. Peng, Y. H. Wang, C. C. Wen, W. H. Wang, C. C. Cheng, Y. H. Chen, “Nephrotoxicity assessments of acetaminophen during zebrafish embryogenesis,” Comp. Biochem. Physiol. C Toxicol. Pharmacol., Vol. 151(4), 480–486, 2010. DOI: https://doi.org/10.1016/j.cbpc.2010.02.004
[13] L. E. Futter, O. A. Al‐Swayeh, P. K. Moore, “A comparison of the effect of nitroparacetamol and paracetamol on liver injury,” Br. J. Pharmacol., Vol. 132(1), 10–12, 2001. DOI: https://doi.org/10.1038/sj.bjp.0703837
[14] I. Ahmad, T. A. Qureshi, F. A. Khan, S. A. Mughal, U. Sadique, Z. Shah, S. Khan, Z. U. Hassan, “Evaluation of biochemical effects of diclofenac sodium in goats,” J. Biosci. Med., Vol. 7(12), 53–60, 2019.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Osama M. EL-barasi, Yousef M. AL-kelany (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Retention of Rights: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
2. User Rights: This license allows others to remix, tweak, and build upon the work non-commercially, and although their new works must also acknowledge the original author and be non-commercial, they do not have to license their derivative works on the same terms.
3. Restrictions: The material cannot be used for commercial purposes without prior written permission from the author or the journal.
4. Additional Agreements: Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository), with an acknowledgement of its initial publication in this journal.
